Dan Moynihan was Appointed as Chief Compliance Officer at

Date of management change: October 12, 2018 

What Happened?

Cambridge, MA-based Appointed Dan Moynihan as Chief Compliance Officer


About the Company

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.


About the Person

Dan Moynihan is Chief Compliance Officer at Akcea Therapeutics. Previously, Dan held various senior legal leadership roles in the industry.


Info Source



Other IT executives who recently changed jobs as well: Williams David, Mourad Christopher, Milstead Melissa, Jones Mike, Cibik Melanie, Vitarelli Anthony, Carrara John, Tollett Cynthia, Dailey Jill, Finkelstein Mark, Catlett Steve

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.